Welcome to our dedicated page for Stereotaxis news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis stock.
Stereotaxis, Inc. (STXS) is a global leader in innovative robotic technologies aimed at improving the treatment of arrhythmias and endovascular procedures. The company's mission focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and information solutions tailored for the interventional laboratory. By leveraging cutting-edge innovations, Stereotaxis helps physicians provide superior patient care with robotic precision and safety, streamline lab efficiency, and enhance procedural information integration.
Stereotaxis boasts over 100 issued patents that form the backbone of its platform. The core components of its systems have received regulatory clearance in various regions including the United States, European Union, Japan, Canada, and China, among others. This broad regulatory approval underscores the global trust and reliance on Stereotaxis' technology.
The company's revenue streams are diversified across systems, disposables, royalties, and subleases, with a significant portion generated from disposables, services, and accessories. Notably, the majority of its revenue is derived from the United States.
Through continuous innovation and dedication to serving the medical community, Stereotaxis remains at the forefront of robotic medical technology, making significant strides in improving procedural outcomes and operational efficiencies in healthcare settings worldwide.
For the latest updates and more information, visit Stereotaxis.
Stereotaxis (STXS) announced the CE Mark submission for its MAGiC™ catheter, a robotically navigated device for cardiac ablation. This innovation aims to enhance precision and safety in treating cardiac arrhythmias. Developed with Osypka, the MAGiC catheter builds on nearly 20 years of experience and over 100,000 procedures. Following CE Mark approval, Stereotaxis plans to launch the catheter commercially in Europe by year-end. The company is also preparing for FDA submission for a U.S. trial. This marks a significant milestone for Stereotaxis and the robotic electrophysiology field.
Stereotaxis (NYSE: STXS) announced the publication of a special issue in the Journal of Atrial Fibrillation & Electrophysiology on Robotic Magnetic Navigation (RMN) for cardiac arrhythmias. The issue features 16 peer-reviewed studies, contributed by physicians from 20 hospitals worldwide, highlighting RMN's clinical benefits. Key topics include the history of RMN, successful patient outcomes, fluoroscopy-free procedures, and advancements in robotic technology. This collaboration aims to enhance awareness and education in electrophysiology, emphasizing the growing importance of robotics in treating arrhythmias.
Stereotaxis (STXS) reported Q1 2022 revenue of $7.0 million, down from $8.6 million in Q1 2021, with system revenue at $1.6 million and recurring revenue at $5.4 million. The gross margin is approximately 70%, with recurring revenue gross margin at 85%. Operating loss increased to ($4.1 million) from ($1.5 million) last year. The company has a cash balance of $36.9 million as of March 31, 2022, with no debt. Despite challenges, Stereotaxis anticipates ongoing revenue growth driven by innovations and capital adoption.
Stereotaxis (NYSE: STXS) announced it will release its 2022 first quarter financial results on May 10, 2022, before U.S. markets open. The company will host a conference call at 10 a.m. EST to discuss the results and corporate developments. Investors can access the call at 888-254-3590 (US) or 1 929-477-0448 (International) using passcode 5168103. A replay will be available for one month after the call. Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, having treated over 100,000 patients globally.
Stereotaxis (NYSE: STXS) announces that Poland's National Institute of Cardiology has launched the first robotic electrophysiology program using the Genesis Robotic Magnetic Navigation (RMN) system, enhancing cardiac arrhythmia treatment. This technology is now operational in 25 countries. A study reports that 3.8% of Warsaw residents aged 20-65 have arrhythmias, indicating over 2 million potential cases in Poland. This initiative aims to improve patient care and advance clinical science in Europe.
Stereotaxis (NYSE: STXS) has inaugurated its new 45,000-square-foot global headquarters in downtown St. Louis, located in the historic Globe Building. This state-of-the-art facility will significantly enhance its surgical robotics operations for minimally invasive endovascular interventions. The headquarters is designed for substantial long-term growth, housing R&D, advanced manufacturing, and distribution capabilities. The event featured demonstrations of their Robotic Magnetic Navigation technology, which has been utilized in over 100 hospitals worldwide.
Stereotaxis (STXS) reported its fourth quarter and full year 2021 financial results, highlighting a 32% revenue growth year-over-year, totaling $35.0 million. The fourth quarter revenue reached $8.2 million, up 21% from the prior year. System revenue saw significant gains, with $11.2 million for the year, reflecting increased adoption of its Genesis RMN systems. The company has a robust innovation pipeline and starts 2022 with $40 million in cash. However, operating losses increased to approximately ($3.4 million) in Q4, and supply chain issues affected new robotic program opportunities.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive interventions, announced that David Fischel, chairman and CEO, will present at three investor conferences in Q1 2022. The presentations include:
- BTIG Virtual Conference on February 15, 2022, at 10:30 am EST
- Aegis Capital Corp. Virtual Conference on February 25, 2022, at 12:00 pm EST
- Cowen Virtual 42nd Annual Health Care Conference on March 8, 2022, at 10:30 am EST
Fischel aims to discuss Stereotaxis' technology and growth strategy with investors.
Stereotaxis (NYSE: STXS) announced plans to release its financial results for Q4 and full year 2021 on March 3, 2022, before the market opens. The company will hold a conference call at 10 a.m. EST to discuss the results and corporate developments. Interested parties can access the call by dialing 866-409-1555 or through the investor relations section of Stereotaxis’ website. The company is a leader in surgical robotics for minimally invasive endovascular interventions, with technology used to treat over 100,000 patients globally.
FAQ
What is the current stock price of Stereotaxis (STXS)?
What is the market cap of Stereotaxis (STXS)?
What does Stereotaxis, Inc. specialize in?
What is the mission of Stereotaxis, Inc.?
Where has Stereotaxis' technology received regulatory clearance?
What are the main revenue streams for Stereotaxis, Inc.?
Who are the key executives at Stereotaxis, Inc.?
How does Stereotaxis' technology benefit physicians?
How many patents does Stereotaxis hold?
What geographic region generates the majority of Stereotaxis' revenue?
What types of procedures are enhanced by Stereotaxis' technology?
Where can I find more information about Stereotaxis, Inc.?
